Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)

University of Groningen, Groningen, Groningen, Netherlands
Kidney International (Impact Factor: 8.52). 07/2005; 67(6):2089-100. DOI: 10.1111/j.1523-1755.2005.00365.x
Source: PubMed

ABSTRACT Chronic kidney disease (CKD) is a worldwide public health problem, with adverse outcomes of kidney failure, cardiovascular disease (CVD), and premature death. A simple definition and classification of kidney disease is necessary for international development and implementation of clinical practice guidelines. Kidney Disease: Improving Global Outcomes (KDIGO) conducted a survey and sponsored a controversies conference to (1) provide a clear understanding to both the nephrology and nonnephrology communities of the evidence base for the definition and classification recommended by Kidney Disease Quality Outcome Initiative (K/DOQI), (2) develop global consensus for the adoption of a simple definition and classification system, and (3) identify a collaborative research agenda and plan that would improve the evidence base and facilitate implementation of the definition and classification of CKD. The K/DOQI definition and classification were accepted, with clarifications. CKD is defined as kidney damage or glomerular filtration rate (GFR) <60 mL/min/1.73 m(2) for 3 months or more, irrespective of cause. Kidney damage in many kidney diseases can be ascertained by the presence of albuminuria, defined as albumin-to-creatinine ratio >30 mg/g in two of three spot urine specimens. GFR can be estimated from calibrated serum creatinine and estimating equations, such as the Modification of Diet in Renal Disease (MDRD) Study equation or the Cockcroft-Gault formula. Kidney disease severity is classified into five stages according to the level of GFR. Kidney disease treatment by dialysis and transplantation should be noted. Simple, uniform classifications of CKD by cause and by risks for kidney disease progression and CVD should be developed.


Available from: Adeera Levin, Jun 05, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Renal involvement is a severe complication in Systemic Lupus Erythematosus (SLE). Moreover, a subset of SLE patients develop the anti-phospholipid syndrome (APS), characterised by the occurrence of anti-phospholipid antibodies (aPL) in combination with macro- and microvascular thrombotic manifestations, including acute and chronic antiphospholipid associated nephropathy (APLN). Clinical presentations of lupus nephritis and APLN are similar and a renal biopsy is necessary to differ between the conditions. Our aim with this study was to investigate the occurrence of histopathological findings consistent with APLN (hAPLN) in renal biopsies from SLE patients and to investigate associations with aPL specificities, clinical manifestations, HLA-DRB1 alleles and long term renal outcome. Consecutive renal biopsies from 112 SLE patients with renal involvement were investigated and evaluated for findings of hAPLN, in all 236 renal biopsies. Data from biopsy reports and clinical information were collected. Autoantibodies against cardiolipin (aCL) and β2glykoprotein1 (β2GP1) were measured by enzyme-linked immunosorbent assay (ELISA). Lupus anticoagulant (LA) test was determined with a modified Dilute Russel Viper Venom method. HLA genotyping was performed by sequence-specific primer-polymerase chain reaction. Renal outcome was determined at study end. The prevalence of hAPLN was 14.3 % among SLE patients with renal involvement. Compared to patients with pure lupus nephritis (LN), occurrence of hAPLN was associated with intima changes (OR = 24, CI:3.0-189.8, p < 0.0001), hypertensive vascular changes (OR:7.8, CI:1.6-39.4, p = 0.01), inflammatory infiltrates (OR = 6.5, CI:1.7-25.1, p = 0.007) and tubular atrophy (OR = 13.1, CI:1.7-103.6, p = 0.002). hAPLN was associated with the presence of aCL antibodies (OR = 3.3, CI:1.0-10.8, p = 0.05) and triple aPL positivity (OR = 4.2, CI:1.3-13.7, p = 0.02). Patients with hAPLN were more hypertensive (OR = 3.8, CI:1.2-12.3, p = 0.03) and had higher levels of creatinine as compared to LN (median 116 vs 75 μmol/L, p < 0.0001). We found significantly higher frequency of HLA-DRB1*13 (OR = 5.1, CI:1.7-15.4, p = 0.03) and development of end stage renal disease (ESRD) (OR = 5.8, CI:1.7-19.7, p = 0.008) in hAPLN in comparison to LN. hAPLN is a severe and often unrecognized condition in SLE patients with renal involvement. We have demonstrated an increased risk for development of renal impairment and a genetic predisposition in hAPLN patients compared to LN patients.
    Arthritis research & therapy 04/2015; 17(1):109. DOI:10.1186/s13075-015-0614-5 · 4.12 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Type 2 diabetes mellitus (T2DM) is the most common cause of chronic kidney disease (CKD) globally. Multiple risk factor management is essential in such patients to delay the disease progression [1]; however, the management of blood glucose presents a particular challenge, with limited treatment options available beyond exogenous insulin therapy [2-5]. Patients with T2DM and CKD are at particular risk of hypoglycemia and its adverse consequences. Dipeptidyl peptidase-4 (DPP-4) inhibitors provide a simple, oral, glucose-sensitive treatment option that does not increase the risk of hypoglycemia and does not confound the comorbidities that afflict many of the other drugs used to treat T2DM [2]. In addition, DPP-4 inhibitors have been shown to be associated with no further decline in estimated glomerular filtration rate (eGFR) when treating patients with CKD [2]. In recent years, several DPP-4 inhibitors have become available and have been extensively evaluated in patients with T2DM and var ...
    03/2015; 6(1). DOI:10.1007/s13300-015-0104-4
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite the minimally invasive nature of transcatheter aortic valve implantation (TAVI), the incidence of acute kidney injury (AKI) and mortality is of major concern. Several studies showed that outcome was influenced by the systemic inflammatory response syndrome (SIRS) in patients undergoing percutaneous TAVI. The purpose of this study was to investigate whether SIRS after transapical TAVI was associated with short-term outcome. Retrospective analysis of prospectively collected data. Intensive care unit in a tertiary-care hospital. In 121 patients undergoing transapical TAVI for severe aortic stenosis between March 2010 and October 2013, the incidence of SIRS during the first 48 hours was studied. The relation between the occurrence of SIRS and any adverse event during hospital stay was investigated. Any adverse event was defined as the composite of mortality, AKI, infection, stroke, myocardial infarction, and bleeding. none. Sixty-five (53.7%) patients developed SIRS during 48 hours after transapical TAVI. The occurrence of SIRS was associated independently with an increased risk of any adverse event (adjusted odds ratio: 4.0, 95% confidence interval [CI]: 1.6-9.6; p = 0.002), which was mainly an increased risk of death (odds ratio: 5.5, 95% CI: 1.1-25.9; p = 0.031). Patients with SIRS had a longer median duration of intensive care unit stay compared with patients without SIRS (2 v 1 day; p<0.001). SIRS predicts short-term outcome in patients undergoing transapical TAVI. Copyright © 2015 Elsevier Inc. All rights reserved.
    Journal of Cardiothoracic and Vascular Anesthesia 04/2015; 29(2). DOI:10.1053/j.jvca.2014.10.005 · 1.48 Impact Factor